Compare CTRM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRM | CTXR |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.9M |
| IPO Year | 2017 | 2010 |
| Metric | CTRM | CTXR |
|---|---|---|
| Price | $1.75 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 40.1K | ★ 562.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $0.63 |
| 52 Week High | $2.65 | $2.38 |
| Indicator | CTRM | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 51.70 |
| Support Level | $1.66 | $0.68 |
| Resistance Level | $2.20 | $0.98 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 20.00 | 58.15 |
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.